BridgeMD
New treatment option for Preeclampsia Postpartum
Official title Aspirin and Preeclampsia
ClinicalTrials.gov ID: NCT04479072
What this study is testing
What is Aspirin 81 mg?
Aspirin 81 mg is an investigational medicine, given as an once-daily, being studied as a potential treatment for preeclampsia postpartum.
Also referred to as acetylsalicylic acid 81 mg.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45, women only
You may be able to join if
- Pregnant Adults between 18 and 45 years of age
- Diagnosed with preeclampsia
- Presenting for delivery with a singleton gestation.
You likely can't join if
- We will exclude patients in labor
- Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic...
- Plan to deliver outside of the participating site
- Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
- Aspirin allergy
- Clear indication for aspirin therapy or contraindication to aspirin therapy
See the full eligibility criteria
- Pregnant Adults between 18 and 45 years of age
- Diagnosed with preeclampsia
- Presenting for delivery with a singleton gestation.
- We will exclude patients in labor
- Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
- Plan to deliver outside of the participating site
- Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
- Aspirin allergy
- Clear indication for aspirin therapy or contraindication to aspirin therapy
- Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
- Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
- Those who cannot provide consent
The study team makes the final eligibility decision.
Where it's taking place
- Chicago, Illinois, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.